{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=14&q=Hodgkin", "query": { "q": "Hodgkin", "condition": "Lymphoma", "page": 14 }, "page_size": 10 }, "pagination": { "page": 14, "page_size": 10, "total_count": 3804, "total_pages": 381, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=15&q=Hodgkin&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Lymphoma&page=13&q=Hodgkin&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-14T14:12:36.936Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05432635", "title": "Genetically Modified T-cells (CMV-Specific CD19-CAR T-cells) Plus a Vaccine (CMV-MVA Triplex) Following Stem Cell Transplantation for the Treatment of Intermediate or High Grade B-cell Non-Hodgkin Lymphoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "B-Cell Non-Hodgkin Lymphoma", "Diffuse Large B-Cell Lymphoma", "Mantle Cell Lymphoma", "Recurrent B-Cell Non-Hodgkin Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Transformed Non-Hodgkin Lymphoma", "Transformed Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Anti-CD19-CAR CMV-specific T-lymphocytes", "type": "BIOLOGICAL" }, { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Multi-peptide CMV-Modified Vaccinia Ankara Vaccine", "type": "BIOLOGICAL" }, { "name": "Myeloablative Conditioning", "type": "PROCEDURE" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE" ], "sponsor": "City of Hope Medical Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 15, "start_date": "2023-08-01", "completion_date": "2028-12-30", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-10-14T14:12:36.936Z", "location_count": 1, "location_summary": "Duarte, California", "locations": [ { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT05432635" }, { "nct_id": "NCT01077518", "title": "Ofatumumab Bendamustine Combination Compared With Bendamustine Monotherapy in Indolent B-cell NHL Unresponsive to Rituxtherapy", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lymphoma, Follicular" ], "interventions": [ { "name": "Ofatumumab", "type": "DRUG" }, { "name": "Bendamustine infusion", "type": "DRUG" }, { "name": "Ofatumumab and Bendamustine infusions (Arm A)", "type": "DRUG" }, { "name": "Bendamustine infusion (Arm B)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 346, "start_date": "2010-08-26", "completion_date": "2018-12-26", "has_results": true, "last_update_posted_date": "2020-03-27", "last_synced_at": "2026-10-14T14:12:36.936Z", "location_count": 18, "location_summary": "Tucson, Arizona • Beverly Hills, California • Palm Springs, California + 15 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "Beverly Hills", "state": "California" }, { "city": "Palm Springs", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Atlanta", "state": "Georgia" } ], "official_url": "https://clinicaltrials.gov/study/NCT01077518" }, { "nct_id": "NCT04712097", "title": "A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Relapsed or Refractory Follicular Lymphoma" ], "interventions": [ { "name": "Mosunetuzumab", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Tociluzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 478, "start_date": "2021-10-27", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-10-08", "last_synced_at": "2026-10-14T14:12:36.936Z", "location_count": 17, "location_summary": "Duarte, California • Atlanta, Georgia • Fort Wayne, Indiana + 13 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Noblesville", "state": "Indiana" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT04712097" }, { "nct_id": "NCT05805605", "title": "Allo HSCT Using RIC and PTCy for Hematological Diseases", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Myelogenous Leukemia", "Acute Lymphocytic Leukemia", "Biphenotypic Acute Leukemia", "Undifferentiated Leukemia", "Prolymphocytic Leukemia", "Chronic Myelogenous Leukemia", "Plasma Cell Leukemia", "Myelodysplastic Syndromes", "Leukemia, Myeloid", "Myelodysplastic Syndrome With Excess Blasts-1", "Burkitt Lymphoma", "Relapsed T-Cell Lymphoma", "Relapsed Chronic Lymphocytic Leukemia", "Small Lymphocytic Lymphoma", "Marginal Zone Lymphoma", "Follicular Lymphoma", "Myeloproliferative Neoplasm", "Myelofibrosis" ], "interventions": [ { "name": "Peripheral Blood Stem Cell Transplant", "type": "BIOLOGICAL" }, { "name": "Allopurinol 300 MG", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Bone Marrow Cell Transplant", "type": "BIOLOGICAL" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Sirolimus Pill", "type": "DRUG" }, { "name": "Mycophenolate Mofetil", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "RADIATION" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "75 Years", "sex": "ALL", "summary": "Up to 75 Years" }, "enrollment_count": 56, "start_date": "2023-05-01", "completion_date": "2028-10-22", "has_results": false, "last_update_posted_date": "2026-07-06", "last_synced_at": "2026-10-14T14:12:36.936Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT05805605" }, { "nct_id": "NCT03361020", "title": "Obstructive Sleep Apnea in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Obstructive Sleep Apnea", "Hodgkin Lymphoma" ], "interventions": [], "intervention_types": [], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 434, "start_date": "2018-01-23", "completion_date": "2028-07-10", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-14T14:12:36.936Z", "location_count": 1, "location_summary": "Memphis, Tennessee", "locations": [ { "city": "Memphis", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03361020" }, { "nct_id": "NCT03935282", "title": "Assessing Effectiveness and Implementation of an EHR Tool to Assess Heart Health Among Survivors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Breast Neoplasm", "Prostatic Neoplasm", "Colorectal Neoplasms", "Endometrial Neoplasms", "Hodgkin Disease", "Non Hodgkin Lymphoma" ], "interventions": [ { "name": "AH-HA Tool in the EPIC EHR", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 645, "start_date": "2020-10-01", "completion_date": "2025-11-17", "has_results": true, "last_update_posted_date": "2026-04-15", "last_synced_at": "2026-10-14T14:12:36.936Z", "location_count": 12, "location_summary": "Fort Smith, Arkansas • Cedar Rapids, Iowa • Ballwin, Missouri + 8 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Cedar Rapids", "state": "Iowa" }, { "city": "Ballwin", "state": "Missouri" }, { "city": "Springfield", "state": "Missouri" }, { "city": "St Louis", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03935282" }, { "nct_id": "NCT02391480", "title": "A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer", "Breast Cancer", "Non-Small Cell Lung Cancer", "Acute Myeloid Leukemia (AML)", "Multiple Myeloma", "Prostate Cancer", "Small Cell Lung Cancer", "Non-Hodgkins Lymphoma" ], "interventions": [ { "name": "ABBV-075", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 128, "start_date": "2015-04-14", "completion_date": "2019-07-05", "has_results": false, "last_update_posted_date": "2019-11-29", "last_synced_at": "2026-10-14T14:12:36.936Z", "location_count": 10, "location_summary": "Scottsdale, Arizona • Duarte, California • Sacramento, California + 6 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT02391480" }, { "nct_id": "NCT03003520", "title": "A Study of Durvalumab in Combination With R-CHOP or Lenalidomide Plus R-CHOP in Previously Untreated High-Risk Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Large B-Cell, Diffuse" ], "interventions": [ { "name": "Durvalumab", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Lenalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2017-02-28", "completion_date": "2022-04-24", "has_results": true, "last_update_posted_date": "2023-05-22", "last_synced_at": "2026-10-14T14:12:36.936Z", "location_count": 7, "location_summary": "Gilbert, Arizona • Fort Wayne, Indiana • Rochester, Minnesota + 4 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Fort Wayne", "state": "Indiana" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Buffalo", "state": "New York" }, { "city": "Rochester", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03003520" }, { "nct_id": "NCT01287741", "title": "A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diffuse Large B-Cell Lymphoma" ], "interventions": [ { "name": "Rituximab", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1418, "start_date": "2011-07-26", "completion_date": "2018-01-31", "has_results": true, "last_update_posted_date": "2019-04-12", "last_synced_at": "2026-10-14T14:12:36.936Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Tucson, Arizona + 32 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Encinitas", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01287741" }, { "nct_id": "NCT00070382", "title": "Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Anemia", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Precancerous/Nonmalignant Condition", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "darbepoetin alfa", "type": "DRUG" }, { "name": "epoetin alfa", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 14, "start_date": "2003-08", "completion_date": null, "has_results": false, "last_update_posted_date": "2020-08-03", "last_synced_at": "2026-10-14T14:12:36.936Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00070382" } ] }